Skip to main content
. 2024 Apr 16;20(8):1132–1139. doi: 10.1200/OP.23.00630

FIG 2.

FIG 2.

RRs comparing HRU between venetoclax and BTKi cohorts in second-line setting. *P < .05; ***P < .0001. BTKi, Bruton tyrosine kinase inhibitor; CI, confidence intervals; CLL, chronic lymphocytic leukemia; ED, emergency department; HRU, health care resource utilization; PPPM, per patient per month; RR, rate ratio.